As you might expect, the competition to win a share of the expanding GLP-1 market is fierce right now, with giants Novo Nordisk ( NVO +0.47%) and Eli Lilly ( LLY +4.57%) slugging it out, while Pfizer ...

A White House deal with Eli Lilly & Co. and Novo Nordisk to lower the prices of their popular obesity medicines, Zepbound and Wegovy, is a step toward making them more affordable and accessible ...

Drugmaker Eli Lilly said it would soon start late-stage trials for eloralintide, a drug mimicking the pancreatic hormone ...

Below, doctors explain everything you need to know about the phenomenon. It’s important to be clear upfront that “Ozempic ...

Medicare will cover GLP-1 weight loss drugs for specific patient groups, beginning in mid-2026, under a deal struck with drugmakers.

After writing dozens of GLP-1 articles over the past year, one issue that consistently comes up is the affordability of ...

A man who fainted in the Oval Office last week was a patient of a weight-loss drug company, according to reports.

There’s plenty to like about the lower direct-to-consumer prices the White House negotiated with Eli Lilly and Novo Nordisk. There are also caveats and some unanswered questions.

Oral GLP-1 weight loss pills could replace injections by March 2026 at $150 monthly, Medicare chief Dr. Mehmet Oz predicted in a FOX Business appearance.

The White Houes may have struck a deal with Eli Lilly and Novo Nordisk last week to lower the costs of their weight loss ...

New versions of drugs like Wegovy, Ozempic, Mounjaro and Zepbound, including pills, will be easier to take, more effective ...

At a time when insurers are backing away from coverage for weight loss medications, President Trump has offered a lifeline ...